About Arontier

Your AI-driven Drug Discovery Partner

Fewer Experiments, Higher Success Rates — design your next drug candidate with AI.

Our Mission & Vision

Drug discovery has long found its answers through countless attempts and repetition. Arontier aims to reach those answers faster and more precisely through AI-based design.

Our AI reinterprets accumulated experimental data in our own way, designing target-specific candidates de novo.

We aim to build a future of drug discovery where every partner reaches success with fewer experiments and higher probability.

Leadership

Junsu Ko

Co-Founder & CEO

Ph.D. in Bioinformatics, Seoul National University

Former Principal Researcher, Theragen Etex Bio Institute

Insuk Sohn

Co-Founder & CSO

Ph.D. in Statistics, Korea University

Former Principal Researcher, Samsung Medical Center

Jooyoung Lee

CTO

Ph.D. in Physical Chemistry, Seoul National University

Professor, College of Pharmacy, Seoul National University

Changha Hwang

CAIO

Ph.D. in Statistics, University of Michigan

Former Professor, Department of Applied Statistics, Dankook University

Woong-Hee Shin

Head of Drug Design

Ph.D. in Chemistry, Seoul National University

Professor, Department of Chemistry, Korea University

Injae Chung

Protein Design Lead

Ph.D. in Structural Biology, University of Cambridge

Former Postdoctoral Researcher, University of Cambridge

Yigu Kim

Head of Platform Development

Ph.D. in Computer Science, University of Arizona

Former Principal Researcher, Theragen Etex Bio Institute

Geunwoo Lee

CAF Drug Development Lead

Ph.D. in Health Sciences and Technology, Sungkyunkwan University

Former Postdoctoral Researcher, Samsung Medical Center

Our Journey

"Structure-Based AI Discovery of Small-Molecule Drug Candidates" project · MSIT 2026.01

'Development of an AI-Driven Lab-in-the-Loop HT Validation and Automation Platform' · KMEDI Hub 2026

'Development of Multi-Factor Integrating AI Agent Digital CRO System for Immunogenicity Prediction' · Ministry of Trade, Industry and Energy 2026

2026
2025

2025.05 "Deeptech Incubator Project for Startup" · Ministry of SMEs and Startups

2025.03 MOU for 'Development of Innovative New Drugs Using AI' · Celltrion Pharma

2025 'Development of Digital Process Design Technology for the Manufacture of AI-Based Targeted Conjugated Drugs' · K-BIO Health

Series-B Bridge investment 2024.07

MOU for 'Development of Innovative New Drugs Using AI' · Dongkook Pharmaceutical 2024.03

'KOREA-US Joint Project of Therapeutics Development' · MOHW 2024

2024
2023

2023.11 'Translational research based on next-generation digital Bio data' · Samsung Medical Center

2023.05 MOU for 'Development of patient-focused innovative drugs using AI' · KMEDI Hub

2023.03 "Development of an AI-Based Antibody Design Platform" project · K-BIO Health

Launch of AD3 2022.10

MOU for 'Development of New innovative drugs using AI' · Samsung Medical Center 2022.10

'AI-based innovative new drug discovery project' · MSIT 2022.06

2022
2021

2021.12 Series-B investment

Series-A investment 2020.11

2020
2019

2019.12 2019 AI Drug Development Platform Project · MSIT

Arontier Founded · Seoul, South Korea · November 2017 2017.11

2017

Join Arontier

We are always looking for passionate scientists and engineers who want to build the future of drug discovery.

View Careers Contact Us